HHS TAGGS · Dec 2024
Synvivia received a $1,640,169 award for a Direct-to-Phase II SBIR project focused on synthetic helper genes and cyclic peptides to improve AAV vector yield and quality for gene therapy manufacturing.
Synvivia applies chemical control over cell behavior
Company research
Public company, workplace, funding, and market signals
Overview
Synvivia is a Berkeley-area synthetic biology biotech that engineers molecules to reprogram cells and uses small-molecule-controlled protein/cyclic-peptide systems to optimize gene-therapy manufacturing, especially AAV yield, potency, and infectiousness.
Primary product
AAV gene-therapy manufacturing optimization platform built around synthetic helper genes, engineered cyclic peptides, and small-molecule-controlled protein switches.
Founded
2015
Headquarters
Berkeley, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Synthetic biology / gene therapy manufacturing tools
Offices
Berkeley, California, United States
Open Positions
0 jobs at Synvivia
No open positions
Check back later for new openings